Pediatric Dermatology

LiVDerm’s 22nd Annual South Beach Symposium Achieves Outstanding Success in Miami Beach

Retrieved on: 
Thursday, February 22, 2024
Education, Pediatric Dermatology, Exhibition, Dermatology, Calendar, Catalog, Learning, Skin care, Faculty, Health, JD, Patient, Master, Knowledge, SBS, Student, Nursing

Hosted side by side, these two annual events brought together leading experts, practitioners, and industry professionals to exchange knowledge, share insights, and advance dermatologic care.

Key Points: 
  • Hosted side by side, these two annual events brought together leading experts, practitioners, and industry professionals to exchange knowledge, share insights, and advance dermatologic care.
  • Attendees had the opportunity to engage with renowned faculty members and explore the latest advances in both medical and cosmetic dermatology.
  • The enhanced exhibition hall served as a hub of innovation and networking, further enriching the symposium experience for all present.
  • "We are thrilled with the success of both symposia and the impact they've had on advancing dermatologic education and patient care.

NEA AWARDS GRANTS FOR ECZEMA RESEARCH TOTALING NEARLY $1 MILLION

Retrieved on: 
Tuesday, December 12, 2023
MSN, Research, Attentional bias, Pediatric Dermatology, Dermatitis, Doctor of Pharmacy, RN, Patient, MSCE, NEA, Science, Pedrá, Harvard College, Atopic dermatitis, Health, National Institutes of Health, NIH, University, MPH, Doctor of Philosophy, Quality of life, Bangladesh Technical Education Board, Inflammation, Pharmaceutical industry, Harbor, Nursing, Management, Boston, MD

NOVATO, Calif., Dec. 12, 2023 /PRNewswire/ -- The National Eczema Association (NEA) today announced the recipients for its 2023 research grants. From both U.S.-based and international applications, the research projects of 18 outstanding investigators were selected, representing grants totaling nearly $1 million. NEA's commitment to innovative eczema research has continued to expand with an increasing number of yearly awardees and an annual investment that has nearly tripled over the past three years.  

Key Points: 
  • From both U.S.-based and international applications, the research projects of 18 outstanding investigators were selected, representing grants totaling nearly $1 million.
  • NEA's commitment to innovative eczema research has continued to expand with an increasing number of yearly awardees and an annual investment that has nearly tripled over the past three years.
  • With 2023 marking the 20th anniversary of its grantmaking, NEA has invested nearly $4 million since its first grant was awarded in 2004.
  • The 2023 research grants were awarded as follows:
    Champion Research Grant– Encourages proven researchers to continue research on emerging or ongoing challenges in eczema or bring their expertise to the field of eczema.

Board-certified Dermatologist Dr. Blair Rose Announces the Launch of Skincare Junkie

Retrieved on: 
Tuesday, October 3, 2023
Weill Cornell Medical Center, Rosacea, Montefiore Medical Center, University, Shareasale, Helsinki University Central Hospital, Business Insider, Salicylic acid, Cowra breakout, Dermatitis, University of California, Irvine School of Medicine, Antioxidant, Merchant, Skin cancer, Pediatric Dermatology, Vogue, Skin, Phthalate, Women's health, American Academy, Hyaluronic acid, Acne, Multimedia, FAAD, Pore, Psoriasis, John Foster Dulles, Journal, PHA, Publication, PRP, Patient, Irritation, Confusion, Albert Einstein College of Medicine, Ceramide, Cosmetics, Dermatology, Elle, MD, Medicine

NEW YORK, Oct. 3, 2023 /PRNewswire/ -- Board certified and award-winning dermatologist Dr. Blair Rose is excited to share the launch of Skincare Junkie , a skincare line that utilizes powerful and clinically proven ingredients in just the right combinations and concentrations to solve common skin problems.

Key Points: 
  • NEW YORK, Oct. 3, 2023 /PRNewswire/ -- Board certified and award-winning dermatologist Dr. Blair Rose is excited to share the launch of Skincare Junkie , a skincare line that utilizes powerful and clinically proven ingredients in just the right combinations and concentrations to solve common skin problems.
  • Dr. Rose created Skincare Junkie out of necessity when she noticed countless patients developing breakouts and skin irritation from popular skincare products.
  • "I needed to create a line of non-toxic, hypoallergenic skincare that I would feel confident suggesting to my patients and that they would enjoy using" says Dr. Rose.
  • Blair Murphy Rose, MD, FAAD , is an award-winning board-certified dermatologist seeing patients in NYC and a clinical instructor of dermatology at the Weill Cornell Medical Center.

Verrica Pharmaceuticals to Host Virtual KOL Event Discussing the Approval of YCANTH™ (Cantharidin) Topical Solution for the Treatment of Molluscum on October 11, 2023

Retrieved on: 
Wednesday, September 27, 2023
KOL, Therapy, Fungal infection, Pediatric Dermatology, Inflammation, Pain, Itch, Mercedes Gonzalez, Sibling, Patient, Molluscum contagiosum, Fomite, Genetically modified bacteria, FDA, Skin, Vaccine, Dermatology, MD

The event will focus on the recent approval of YCANTH™ as the only product approved by the FDA to treat molluscum in adult and pediatric patients two years of age and older.

Key Points: 
  • The event will focus on the recent approval of YCANTH™ as the only product approved by the FDA to treat molluscum in adult and pediatric patients two years of age and older.
  • Molluscum is caused by a pox virus that produces distinctive raised, skin-toned-to-pink-colored lesions that can cause pain, inflammation, itching and bacterial infection.
  • It is easily transmitted through direct skin-to-skin contact or through fomites and can spread to other parts of the body or to other people, including siblings.
  • Without treatment, molluscum can last for an average of 13 months, and in some cases, up to five years.

LiVDerm’s Acclaimed Dermatology Conference, the South Beach Symposium, Returns to Miami Beach This February

Retrieved on: 
Monday, August 21, 2023
SBS, Business development, Education, JAK, Catalog, Curriculum, Clinical trial, Dermatology, Pediatric Dermatology, Acne, Atopic dermatitis, Research, Student, MD, Patient, JD, Adolescence, Diagnosis, Knowledge, BOTH, Health, Master, Nursing, Medical device

As such, this year’s theme has been aptly named to convey this all-important message - Bridging Medical and Aesthetic Dermatology.

Key Points: 
  • As such, this year’s theme has been aptly named to convey this all-important message - Bridging Medical and Aesthetic Dermatology.
  • Renowned dermatologists, Michael H. Gold, MD , and David J. Goldberg, MD, JD , also return as co-chairs for the South Beach meeting.
  • Both specialists are lauded for their clinical and research accomplishments across the dermatology space.
  • We are excited for February's agenda which brings the nation's top experts from both sides of dermatology."

LiVDerm Officially Launches MOPD Foundations of Pediatric Dermatology Certificate Course

Retrieved on: 
Thursday, July 20, 2023
Certificate of Completion of Training, PAS, Catalog, Pediatric Dermatology, MS, Dermatology, DO, Student, Patient, Practitioner, Adolescence, Knowledge, MPH, Completion, Pediatrics, Skin, Master, Nursing, MD

Boca Raton, FL, July 20, 2023 (GLOBE NEWSWIRE) -- On Saturday, July 15, LiVDerm went live with its brand-new and fully online training program, the MOPD Foundations of Pediatric Dermatology Certificate Course .

Key Points: 
  • Boca Raton, FL, July 20, 2023 (GLOBE NEWSWIRE) -- On Saturday, July 15, LiVDerm went live with its brand-new and fully online training program, the MOPD Foundations of Pediatric Dermatology Certificate Course .
  • Created by the founders of the Masters of Pediatric Dermatology (MOPD) Symposium, this self-paced program is designed to enhance clinicians’ foundational knowledge of pediatric dermatology and provide learners with the tools they need to better care for their young patients.
  • Led by world-renowned medical, aesthetic, and pediatric dermatology experts, LiVDerm empowers providers to educate, collaborate, and engage.
  • With a multipronged approach to mastering the myriad of subspecialties within the field, LiVDerm provides innovative and integrated education across the dermatology spectrum.

Pediatric Dermatology of Kansas City Joins Epiphany Dermatology

Retrieved on: 
Monday, July 10, 2023
Health, Consumer, Hospitals, Surgery, Other Health, Children, General Health, Partnership, University, Marketing, Dermatology, Pediatric Dermatology, Case Western Reserve University, MD, Patient, Entrepreneurship, University of Wisconsin School of Medicine and Public Health, Nursing, Kansas City metropolitan area, Epiphany

Epiphany Dermatology, a leading dermatology company committed to improving access to exceptional dermatologic care, announced today it has expanded its presence in the Kansas City market through its partnership with Sue Ann Douglas, MD, and her team at Pediatric Dermatology of Kansas City, based in Mission Woods, Kansas.

Key Points: 
  • Epiphany Dermatology, a leading dermatology company committed to improving access to exceptional dermatologic care, announced today it has expanded its presence in the Kansas City market through its partnership with Sue Ann Douglas, MD, and her team at Pediatric Dermatology of Kansas City, based in Mission Woods, Kansas.
  • Founded in 2019 by Dr. Sue Ann Douglas, Pediatric Dermatology of Kansas City has a solid reputation of providing individualized and high-quality pediatric dermatology care to patients in the greater Kansas City marketplace.
  • I take great pride and responsibility in treating pediatric patients in the greater Kansas City market and entering this partnership will benefit our community.
  • Epiphany also benefits from the clinical expertise of Pediatric Dermatology of Kansas City’s team, as best practices are collaboratively shared across the Epiphany network.

Timber Pharmaceuticals to Present Interim Analyses From Phase 3 ASCEND Study of TMB-001 in Congenital Ichthyosis

Retrieved on: 
Tuesday, June 20, 2023
Tretinoin, PK, Society, Dermis, Stanford University, Must, Food, CI, XLRI, Epidermis, Pediatric Dermatology, Dermatology, Toxicity, Absorption, Plasma, Ichthyosis, IGA, Professor, ASCEND, Patient, Collection, Lumber, Isotretinoin, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NYSE, Skin, Safety, ARCI, Body surface area, Pharmaceutical industry

WARREN, NJ, June 20, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that interim pharmacokinetic (PK) analyses from the Phase 3 ASCEND study indicate minimal systemic absorption of isotretinoin or its major metabolites in patients with moderate to severe forms of congenital ichthyosis (CI) who were treated with TMB-001 0.05% ointment. Full PK results will be presented during the Society for Pediatric Dermatology’s Annual Meeting to be held July 13-16, 2023, in Asheville, North Carolina.

Key Points: 
  • Full PK results will be presented during the Society for Pediatric Dermatology’s Annual Meeting to be held July 13-16, 2023, in Asheville, North Carolina.
  • The primary endpoint is the difference in proportions of treated patients with 2-point Investigator's Global Assessment (IGA) scaling/fissuring score improvement from baseline at 12 weeks.
  • The interim PK analyses include the first nine patients who completed 15 days of the MuST study.
  • The results indicate minimal absorption of isotretinoin when TMB-001 0.05% is applied to 75-90% of the body surface area.

Dr. Michele L. Ramien takes the helm as President of the Canadian Dermatology Association

Retrieved on: 
Monday, June 19, 2023
Royal college, University, Physician, Toronto, Pediatric Dermatology, Boston, St George Hospital, Mumbai, University of Ottawa Heart Institute, Certification, CDA, CHU, American Board of Commissioners for Foreign Missions, Royal College of Physicians and Surgeons of Canada, American Board of Dermatology, Hospital, Surgeon, McGill University, Nursing, Dermatology

OTTAWA, June 19, 2023 (GLOBE NEWSWIRE) -- The Canadian Dermatology Association (CDA) is proud to announce the appointment of Dr. Michele L. Ramien as CDA President, effective June 16, 2023.

Key Points: 
  • OTTAWA, June 19, 2023 (GLOBE NEWSWIRE) -- The Canadian Dermatology Association (CDA) is proud to announce the appointment of Dr. Michele L. Ramien as CDA President, effective June 16, 2023.
  • Dr. Ramien plans to advocate for, protect, and support the interests of Certified Dermatologists and the specialty of dermatology during her appointment as President.
  • Dr. Ramien brings strategic leadership, clinical expertise, and a growth-oriented mindset to the CDA, and has held previous positions as President Elect and Vice-President of the association.
  • The CDA welcomes Dr. Ramien as President, Canadian Dermatology Association for a one-year term.

CELEBRATING 20 YEARS OF RESEARCH FUNDING, THE NATIONAL ECZEMA ASSOCIATION WILL AWARD $1 MILLION IN 2023

Retrieved on: 
Wednesday, April 12, 2023
Life, Dermatitis, Pediatric Dermatology, Quality of life, PDT, Atopic dermatitis, Research, Inflammation, National Institutes of Health, Bangladesh Technical Education Board, Science, NEA, Patient, Biology, Health, Pedrá, NIH, Disease, Pharmaceutical industry

NOVATO, Calif., April 12, 2023 /PRNewswire/ -- The National Eczema Association (NEA) today announced that it will award $1 million in research grants this year to researchers studying all aspects of eczema. In its twenty years of research funding, NEA has continued to increase investment in its research grants, more than doubling the amount in two years, with new grant categories to fund more investigators in various stages of their careers.

Key Points: 
  • NOVATO, Calif., April 12, 2023 /PRNewswire/ -- The National Eczema Association (NEA) today announced that it will award $1 million in research grants this year to researchers studying all aspects of eczema.
  • As the largest private nonprofit funder of eczema research, NEA has invested over $3 million since its first grant was awarded in 2004.
  • Most notably, for every $1 NEA has invested in eczema research, grantees have collectively gone on to obtain an additional $10.12 in subsequent National Institutes of Health (NIH) funding to support further eczema research.
  • The 2023 research grant categories are as follows:
    Impact Research Grant – Provides funding support for collaborative research projects to conduct multi-institution innovative eczema research.